Shah Gul Zahra

Ms. Shah Gul Zahra


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 December 2023 in Brain Sciences
Verified
Journal Article
Open access
PDF file
MFMinaam Farooq
Minaam Farooq
Gianluca ScaliaGianluca Scalia
Gianluca Scalia
Giuseppe Emmanuele UmanaGiuseppe Emmanuele Umana
Giuseppe Emmanuele Umana
UPUrja Parekh
Urja Parekh
FNFaiza Naeem
Faiza Naeem
Bipin ChaurasiaBipin Chaurasia
Bipin Chaurasia
Background: Glioblastoma (GBM) is categorized as a grade IV astrocytoma by the World Health Organization (WHO), representing the most aggressive and prevalent form of glioma. It presents a significant clinical challenge, with limited treatment options and poor prognosis. This systematic review evaluates the efficacy and safety of various nanotherapy approaches for GBM and explores future directions in tumor management. Nanomedicine, which involves nanoparticles in the 1–100 nm range, shows promise in improving drug delivery and targeting tumor cells. Methods: Following PRISMA guidelines, a systematic search of databases including Google Scholar, NCBI PubMed, Cochrane Library, and ClinicalTrials.gov was conducted to identify clinical trials on GBM and nanomedicine. The primary outcome measures were median overall survival, progression-free survival, and quality of life assessed through Karnofsky performance scores. The safety profile was assessed by adverse events. Results: The analysis included 225 GBM patients, divided into primary and recurrent sub-populations. Primary GBM patients had a median overall survival of 6.75 months, while recurrent GBM patients had a median overall survival of 9.7 months. The mean PFS period was 2.3 months and 3.92 months in primary GBM and recurrent GBM patients, respectively. Nanotherapy showed an improvement in quality of life, with KPS scores increasing after treatment in recurrent GBM patients. Adverse events were observed in 14.2% of patients. Notably, Bevacizumab therapy exhibited better survival outcomes but with a higher incidence of adverse events. Conclusions: Nanotherapy offers a modest increase in survival with fewer severe side effects. It shows promise in improving the quality of life, especially in recurrent GBM patients. However, it falls short in terms of overall survival compared to Bevacizumab. The heterogeneous nature of treatment protocols and reporting methods highlights the need for standardized multicenter trials to further evaluate the potential of nanomedicine in GBM management.


8 July 2022 in Surgical Neurology International
Verified
Journal Article
Open access
UKUsman Ahmad Kamboh
Usman Ahmad Kamboh
MAMohammad Ashraf
Mohammad Ashraf
SZShah Gul Zahra
Shah Gul Zahra
MRMuhammad Asif Raza
Muhammad Asif Raza
MMMehwish Manzoor
Mehwish Manzoor
NANaveed Ashraf
Naveed Ashraf
Background: Congenital muscular torticollis (CMT) is a common musculoskeletal anomaly that can be excellently managed at birth with conservative physiotherapy; as a result, literature on neglected cases of CMT in older patients is sparse, and there is controversy regarding the ideal surgical approach. This report aims to provide the outcome of 28 adolescent patients with neglected CMT who underwent unipolar release at the distal sternocleidomastoid muscle (SCM). Methods: Twenty-eight adolescent patients with untreated CMT presented to our department between 2016 and 2019 and underwent unipolar release at the distal end of their SCM. All patients had no other anomaly based on clinical examination and radiological investigations. At the time of surgery, the mean age of patients was 15.8 years (range 13–18 years). There were 10 male and 18 female patients with the right side affected in 20 cases. All patients were followed up for 2 years. Patients were evaluated using an adapted version of the modified Lee’s scoring system to assess cosmesis and the cervical-mandibular angle (CMA) to assess radiological change. Results: The adapted modified Lee’s scoring system indicated 17 patients (60.7%) had an excellent outcome, 6 patients (21.4%) had a good outcome, and 5 patients (17.9%) had a fair outcome. In particular, scarring was fine in 23 patients (82.1%) and only slight in the remaining. Independent to the categorical outcome, all patients subjectively reported high satisfaction with their cosmesis. The preoperative mean CMA was 19.6° (range, 8.5–31.5°), which was reduced to a mean of CMA of 14.0° (range, 3–28°) after surgery (P < 0.05). No patient developed any permanent complication or required surgery for recurrence. No serious postoperative complications such as infection or hematoma were observed. Conclusion: In uncomplicated cases of neglected CMT in adolescent patients, unipolar tenotomy of the distal SCM is a safe and reliable technique with good clinical outcomes.

8 November 2023 in Brain and Spine
Verified
Journal Article
Open access
MFMinaam Farooq
Minaam Farooq
STSunaina Tariq
Sunaina Tariq
SZShah Gul Zahra
Shah Gul Zahra
Oday AtallahOday Atallah
Oday Atallah
Bipin ChaurasiaBipin Chaurasia
Bipin Chaurasia

6 January 2023 in Surgical Neurology International
Verified
Journal Article
Open access
MAMohammad Ashraf
Mohammad Ashraf
GNGhulam Naseeruddin
Ghulam Naseeruddin
SZShah Gul Zahra
Shah Gul Zahra
KSKashif Ali Sultan
Kashif Ali Sultan
UKUsman Ahmad Kamboh
Usman Ahmad Kamboh
NANaveed Ashraf
Naveed Ashraf
Background: Chronic myeloid leukemia (CML) is mostly asymptomatic at diagnosis. Intracerebral hemorrhage (ICH), as the first presentation of CML in its chronic phase (CP) has only once been reported in the literature. In addition, CML (CP) patients developing ICH are equally rare, with only eight cases reported. ICH is more commonly associated with CML progressing to its end stage (accelerated phase [AP] and blast crisis [BC]). The pathophysiology of ICH in CML-CP is postulated to be due to leukostasis, unlike in the CML-AP/BC, where thrombocytopenia and coagulopathy are the underlying mechanisms. This case adds to the scarce literature on a rare and challenging complication of ICH in CML-CP, especially as these patients tend to rebleed and management is uncertain. Case Description: A 22-year-old male presented with a 2-week history of headaches and vomiting, associated with a 1-week history of the left-sided weakness. Initial blood work revealed hyperleukocytosis. The patient was investigated for CML with intracranial involvement. During his stay, his Glasgow coma score (GCS) dropped (from 14 to 11), prompting an urgent CT scan which revealed a large resolving ICH with perifocal edema and midline shift. A decompressive hemicraniectomy with expansion duraplasty was performed to alleviate the mass effect and reduce intracranial pressure. Three hours postoperatively, the patient developed an extradural hematoma which needed prompt evacuation. A postoperative CT revealed an improved midline shift, and after 7 days, his GCS improved to 15, and he began oncological treatment. Neurological symptoms were experienced by our patient at presentation with hyperleukocytosis on full blood count, which may implicate leukostasis as an underlying mechanism. Conclusion: Even in the CP, CML patients presenting with mild neurological symptoms should be investigated to exclude intracranial bleeds. As these patients tend to rebleed, they should be conservatively managed unless there is a need to alleviate intracranial pressure.

6 June 2023 in Asian Journal of Neurosurgery
Verified
Journal Article
Open access
PDF file
MAMohammad Ashraf
Mohammad Ashraf
SZShah Gul Zahra
Shah Gul Zahra
MFMinaam Farooq
Minaam Farooq
NCNabeel Choudhary
Nabeel Choudhary
NANaveed Ashraf
Naveed Ashraf
Dear Editor, We read with great interest Malikov et al's case report/technical note entitled “PMMA cranioplasty making by using open-source CAD software, PLA printers, and silicone rubber molds: technical note with two illustrative cases.”[1] We were the first in the literature to begin an ultra-low-cost patient-specific polymethyl methacrylate (PMMA) cranioplasty implant service in Pakistan, that too in a public sector hospital, and we have already published our technical note and limited case series with 1-year follow-up.[2] Since then, our technique has been adopted by our colleagues at neighboring centers, and we have amassed an experience of over 50 cases, and many of our patients are in long-term follow-up. At the national level, the lowest cost offered by commercial companies for a patient-specific PMMA implant exceeded US$ 1,000 and US$ 10,000 for titanium and polyetheretherketone (PEEK) hemicraniectomy implants, respectively. The vast majority of the Pakistani population are poor and underprivileged, and the trauma cohort who require this operation are actually those who could never meet these costs in their lifetime. Free-hand PMMA cranioplasty was utilized in virtually all cases nationally. After beginning our initial service, the total cost to manufacture an implant in consumables was US$ 40. The printer we used was a locally assembled Chinese Prusa i3 clone. Thus, production cost was exponentially cheaper than commercial rates, and in our experience, our clinical and aesthetic outcomes are the same, if not better. Naturally, when one intends to offer a service for the patient benefit rather than profit, affordability is one of the most important parameters, especially in the impoverished developing world. We would be delighted to know the exact specification of the printer used by Malikov et al, the cost of disposables and printing of each implant, and the context of this cost in their patient's socioeconomic demographic/health care system, and whether commercial options were as extortionate for their general public as it was for ours. Once we began this service, we became a national referral center. The service began with a single neurosurgeon, without any formal IT training, experimenting, and printing these implants with an ambition to advance global neurosurgery. We now require the resources for a full-time service. This means the need for a departmental printer, arguably of a better spec to the bare minimum leisure 3D printer used at home, and capacity building by training clinical fellows and residents in the design process to meet the demands for national service in a timely fashion. It would be interesting to learn more about Malikov et al's exact workflow and cost breakdowns. Is the authors' patient-specific PMMA cranioplasty service in a public sector hospital? Do the patients have to pay out of their pocket for these implants? If this is a public sector service, has the author's volume of referrals increased, and if so, how are they coping with meeting the demands? Finally, it would be of great use to hear the authors' experience on the learning curve with these open-access software packages, which are arguably not as user-friendly as the purpose-built (but much more costly!) software. In our own experience, when began this service, we initially found even simple implant designing difficult, but within the space of 10 to 20 patients, we have been proficient in the design process of even complex orbital defects, including neurofibromatosis type 2 and plexiform tumors that require radical tumor resection and subsequent skull base reconstruction. Perhaps instead of paper-based publications/technical notes offering limited information, we should produce virtual tutorials and online workshops that teach viewers the design process in enough detail to equip them to begin such a service if required in their local setup. We congratulate the authors on beginning this service in their country and wish them all the best in advancing global neurosurgery. Article published online: 06 June 2023 © 2023. Asian Congress of Neurological Surgeons. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/) Thieme Medical and Scientific Publishers Pvt. Ltd. A-12, 2nd Floor, Sector 2, Noida-201301 UP, India